NextGenNK
NextGenNK is a Competence Center for the development of next generation NK cell-based cancer immunotherapies. The Center is coordinated by Karolinska Institutet and collaborates with the Karolinska University Hospital and prominent national and international industrial partners. The Center was launched in 2020, and is jointly funded by Vinnova, KI, and the Industrial partners.
News
Upcoming events
First patient included in phase II study in multiple myeloma
First patient included in phase II study in multiple myeloma
The first patient has been included in a phase II clinical study to treat patients with multiple myeloma using autologous NK cell-based candidate drug in combination with Sarclisa (Isatuximab).
Learn the basics of ATMPs
Learn the basics of ATMPs
What do you know about ATMPs? Equip yourself for the future – learn the basics of Advanced Therapy Medicinal Products (ATMP).
Newsletter #3 from NextGenNK
Newsletter #3 from NextGenNK
In the latest newsletter from the Director you can read about what is ongoing in the Competence Center. We are also highlighting the Swedish SME - XNK Therapeutics AB.